Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection

Affiliations

Case Reports

R F Jeffrey et al. Transplantation. 1993 Mar.

. 1993 Mar;55(3):677-9.

¹ Department of Renal Medicine, St. James's University Hospital, Leeds, England.

No abstract available

Similar articles

Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C, Hazzan M, Coppin MC, Pruvot FR, Bridoux F, Lelièvre G. Noël C, et al. Transplant Proc. 1995 Aug;27(4):2438-9. Transplant Proc. 1995. PMID: 7652870 No abstract available.
Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine E, Bellakoul R, Berthoux F. Alamartine E, et al. Transplant Proc. 1994 Feb;26(1):273-4. Transplant Proc. 1994. PMID: 8108975 Clinical Trial. No abstract available.
Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
Piatosa B, Grenda R, Prokurat S. Piatosa B, et al. Transplant Proc. 1993 Aug;25(4):2574. Transplant Proc. 1993. PMID: 8356675 Clinical Trial. No abstract available.
OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR, Schroeder TJ, Hariharan S. First MR, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):25-6. Transplant Proc. 1993. PMID: 8465417 Review. No abstract available.
Rationale for OKT3 monoclonal antibody treatment in transplant patients.
Norman DJ. Norman DJ. Transplant Proc. 1993 Apr;25(2 Suppl 1):1-3. Transplant Proc. 1993. PMID: 8465414 Review. No abstract available.